Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Gastric Cancer|Gastroesophageal Junction Cancer
Interventions: BIOLOGICAL: ZW25|DRUG: Docetaxel|BIOLOGICAL: Tislelizumab|DRUG: Capecitabine|DRUG: Oxaliplatin
Sponsor: BeiGene